» Articles » PMID: 19123868

The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options

Overview
Journal Clin Infect Dis
Date 2009 Jan 7
PMID 19123868
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Up to 30% of human immunodeficiency virus (HIV)-infected patients who are receiving long-term highly active antiretroviral therapy do not exhibit a marked increase in the CD4(+) T cell count, despite achieving complete suppression of the HIV load. These patients are referred to as "immunological nonresponders." When treating immunological nonresponders, the practicing clinician has several questions, including questions about the clinical risk associated with persistent immunodeficiency and about possible approaches to treatment that would provide clinical and immunological benefits. However, tentative answers to these questions require investigations of the mechanisms that underlie the lack of immune recovery, because only the deepest comprehension of the immunological gaps underlying functional defects will allow administration of highly targeted and efficacious treatment strategies. The aim of our review is to provide a thorough assessment of the clinical implications of a lack of increase in the CD4(+) T cell count in immunological nonresponders, to examine the immunological gaps limiting recovery of the CD4(+) T cell count, and to note possible therapeutic avenues, which may offer clinicians guidance regarding how to most efficaciously treat these critical patients.

Citing Articles

No Association Between HIV-1 Subtype and Primary Resistance Mutations with CD4 Reconstitution During Effective Antiretroviral Treatment: An Observational, Cohort Study.

Zaleski A, Lembas A, Dyda T, Osinska J, Jablonska J, Stempkowska-Rejek J Int J Mol Sci. 2025; 26(4).

PMID: 40003876 PMC: 11855707. DOI: 10.3390/ijms26041410.


CD24-Fc resolves inflammation and rescues CD8 T cells with polyfunctionality in humanized mice infected with HIV-1 under cART.

Li G, Ma J, Yu H, Tsahouridis O, Lou Y, He X bioRxiv. 2025; .

PMID: 39763958 PMC: 11702585. DOI: 10.1101/2024.12.16.628615.


Population-Specific Predictors of Immunologic Reconstitution Following Initiation of Combined Antiretroviral Therapy in Children: A Retrospective Observational Study from a 15-Year Cohort of HIV-Positive Children and Adolescents in Eritrea.

Ghebremeskel G, Mengistu S, Tsegai M, Mehretab A, Kidane H, Abraham Y HIV AIDS (Auckl). 2024; 16:433-453.

PMID: 39524019 PMC: 11550920. DOI: 10.2147/HIV.S483094.


Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV.

Chen C, Wang J, Xun J, Zhang X, Liu L, Song Z BMC Infect Dis. 2024; 24(1):97.

PMID: 38233816 PMC: 10792804. DOI: 10.1186/s12879-024-08985-y.


The immune response to SARS-CoV-2 in people with HIV.

Hoft M, Burgers W, Riou C Cell Mol Immunol. 2023; 21(2):184-196.

PMID: 37821620 PMC: 10806256. DOI: 10.1038/s41423-023-01087-w.